Health.Zone Web Search

Search results

1. Results from the Health.Zone Content Network

2. C4 Therapeutics Appoints Veteran Biotechnology Leader Stephen ...

   lite.aol.com/tech/story/0022/20240903/9223475.htm

   WATERTOWN, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced the continued evolution of its Board of Directors with the appointment of Stephen (Steve) Fawell, Ph.D. as a director.

3. C4 Therapeutics Reports Second Quarter 2024 Financial Results ...

   lite.aol.com/tech/story/0022/20240801/9197005.htm

   WATERTOWN, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, reported financial results today for the second quarter ended June 30, 2024, as well as recent business highlights.

4. C4 Therapeutics Presents Monotherapy Data Demonstrating Proof ...

   lite.aol.com/tech/story/0022/20240913/9230199.htm

   WATERTOWN, Mass., Sept. 13, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced initial clinical data from the ongoing clinical trial of CFT1946, an orally bioavailable small molecule degrader of BRAF V600 ...

5. C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Tops Revenue ...

   www.aol.com/news/c4-therapeutics-inc-cccc...

   C4 Therapeutics, Inc. (CCCC) delivered earnings and revenue surprises of 17.65% and 77.56%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

6. What Is The Ownership Structure Like For C4 Therapeutics, Inc ...

   www.aol.com/news/ownership-structure-c4...

   The big shareholder groups in C4 Therapeutics, Inc. ( NASDAQ:CCCC ) have power over the company. Institutions will...

7. Growth Investors: Industry Analysts Just Upgraded Their C4 ...

   www.aol.com/news/growth-investors-industry...

   Shareholders in C4 Therapeutics, Inc. ( NASDAQ:CCCC ) may be thrilled to learn that the analysts have just delivered a... Growth Investors: Industry Analysts Just Upgraded Their C4 Therapeutics ...

8. Nathanael Gray - Wikipedia

   en.wikipedia.org/wiki/Nathanael_Gray

   Nathanael S. Gray is an American chemist. He serves as Krishnan-Shah Family Professor of chemical and systems biology at Stanford University [1] and director of cancer therapeutics programme at Stanford University School of Medicine. [2] Previously he was a Nancy Lurie Marks Professor of biological chemistry and molecular pharmacology at ...

9. Anacetrapib - Wikipedia

   en.wikipedia.org/wiki/Anacetrapib

   Main page; Contents; Current events; Random article; About Wikipedia; Contact us; Donate; Help; Learn to edit; Community portal; Recent changes; Upload file